ストックスクリーナーアプリを入手
49.56
0.48%
-0.26
前日終値:
$49.82
開ける：
$50.07
24時間の取引高:
13,869
Relative Volume:
0.05
時価総額：
$3.16B
収益：
-
当期純損益:
$-54.80M
株価収益率:
-42.39
EPS:
-1.1692
ネットキャッシュフロー:
$-64.65M
1週間 パフォーマンス:
-5.56%
1か月 パフォーマンス:
+1.14%
6か月 パフォーマンス:
+27.03%
1年 パフォーマンス:
+15.65%
1日の値動き範囲:
$48.91
$51.13
1週間の範囲:
$47.33
$52.24
52週間の値動き範囲:
$37.55
$64.98
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
MLTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| MLTX | 49.56 | 3.16B | 0 | -54.80M | -64.65M | -1.1692 |
| VRTX | 448.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.76 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.05 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.12 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.07 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN
MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics' SWOT analysis: biopharma stock faces HS market potential, execution risks - Investing.com Canada
(MLTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics announces first patients screened in IZAR program - TipRanks
MoonLake Launches Major Phase 3 Trials for Psoriatic Arthritis Drug After Strong Phase 2 Results | MLTX Stock News - StockTitan
FMR LLC's Strategic Acquisition of MoonLake Immunotherapeutics S - GuruFocus.com
MoonLake Immunotherapeutics (MLTX) Quarterly 10-Q Report - Quartzy
MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Q3 Earnings Forecast for MLTX Issued By Wedbush - Defense World
What is Wedbush's Forecast for MLTX Q3 Earnings? - MarketBeat
MoonLake Immunotherapeutics reports Q3 EPS (56c), consensus (43c) - TipRanks
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to "Strong-Buy" at Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
AlphaCentric Advisors LLC Invests $706,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
75,469 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by Rice Hall James & Associates LLC - MarketBeat
MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN
I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St
(MLTX) Proactive Strategies - Stock Traders Daily
HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares - Investing.com India
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold (NASDAQ:MLTX) - Seeking Alpha
When (MLTX) Moves Investors should Listen - Stock Traders Daily
MoonLake Immunotherapeutics [MLTX] stock for 100,003,200 USD was sold by BVF PARTNERS L P/IL - Knox Daily
MLTX’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing MoonLake Immunotherapeutics (MLTX)’s Performance - The Dwinnex
What is MLTX’s price-to-sales ratio telling us about the company’s value? - US Post News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down on Insider Selling - Defense World
Millennium Management LLC Has $9.54 Million Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Biotechnology value fund L P executives sell over $100 million in MoonLake Immunotherapeutics shares - Investing.com India
MoonLake Immunotherapeutics director sells shares worth over $9m - Investing.com
Insider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 171,000 Shares of Stock - Defense World
Simon Sturge Sells 171,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
MoonLake Immunotherapeutics director sells shares worth over $9m By Investing.com - Investing.com UK
Director Simon Sturge Sells 171,000 Shares of MoonLake Immunothe - GuruFocus.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 8.3%Here's What Happened - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Position Increased by The Manufacturers Life Insurance Company - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
MLTX’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
Moonlake Immunotherapeutics (MLTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
| Santos da Silva Jorge | Chief Executive Officer |
Feb 27 '24 |
Sale |
55.00 |
62,810 |
3,454,550 |
3,043,619 |
| Santos da Silva Jorge | Chief Executive Officer |
Feb 28 '24 |
Sale |
55.00 |
56,065 |
3,083,575 |
2,987,554 |
| Santos da Silva Jorge | Chief Executive Officer |
Feb 29 '24 |
Sale |
55.89 |
4,740 |
264,919 |
2,982,814 |
| Reich Kristian | Chief Scientific Officer |
Feb 28 '24 |
Sale |
55.00 |
31,910 |
1,755,050 |
2,925,573 |
| Reich Kristian | Chief Scientific Officer |
Feb 27 '24 |
Sale |
55.00 |
29,491 |
1,622,005 |
2,957,483 |
| Reich Kristian | Chief Scientific Officer |
Feb 27 '24 |
Sale |
55.00 |
29,431 |
1,618,705 |
70,071 |
| Reich Kristian | Chief Scientific Officer |
Feb 28 '24 |
Sale |
55.00 |
28,090 |
1,544,950 |
41,981 |
| Santos da Silva Jorge | Chief Executive Officer |
Feb 21 '24 |
Sale |
55.27 |
1,125 |
62,179 |
3,106,429 |
| Reich Kristian | Chief Scientific Officer |
Feb 20 '24 |
Sale |
57.45 |
10,000 |
574,500 |
2,987,483 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):